

DR. ROBERT BROOKINS CONFIRMED AS CEO & MD Richard Estes Promoted to VP of Research and Development

Highlights:

- The Board is delighted to announce the appointment of Dr. Robert Brookins as Chief Executive Officer and as Managing Director of Alexium International Group Limited (the "Company");
- Dr. Brookins has been instrumental in the development of the Company's innovative technologies, including its:
 - phase change material ("PCM") technologies and Alexicool® product line; and
 - flame retardant ("FR") technologies;
- Dr. Brookins has, during the past 8 years, worked across all areas of the Company's operations, including commercialization, sales, product development, and supply chain management, and has the skills and experience to lead the Company in the continued development and commercialization of its technologies; and
- Alexium is also delighted to announce the appointment of Mr. Richard Estes as Vice President of Research and Development.

Perth, Australia, and Greer, South Carolina - 12 July 2018- Alexium International Group Limited ("Alexium," "the Company," ASX: AJX, NASDAQ Designation: AXXIY) has appointed Dr. Robert (Bob) Brookins as Chief Executive Officer and Managing Director of the Company.

In his capacity as Executive Vice President of Research and Development, Dr. Brookins has been instrumental in the research and development of the Company's innovative technologies. Dr. Brookins led the development and commercialization of Alexium's phase change material ("PCM") platform technologies and the Alexicool® product line, which is the foundation of the Company's recent success in sales to the bedding and top-of-bed markets. Dr. Brookins has, during his 8 years with the Company, been involved in multiple facets of the business, including working with customers on product design and marketing, analysing markets to assess opportunities, and planning for logistics and supply-chain management. In addition, Dr. Brookins co-invented Alexium's flame retardant ("FR") technologies for military uniforms and formaldehyde-free, flame retardant products for cotton-based materials. Dr. Brookins has been immersed in the operations and strategy of the business and has gained significant experience working within the senior leadership team of the Company.

Dr. Brookins has demonstrated an entrepreneurial drive, a deep knowledge of Alexium's business and markets, and strong leadership to drive the vision and performance of the Company. He is committed to strategic decision making, transformative business and organizational process, and effective cost management.

Over the past two years, Dr. Brookins has assembled a strong Research & Development team which has been integral to the development of the Company's proprietary technologies. Mr. Richard Estes has been a critical person in this team including as co-inventor with Dr. Brookins on the PCM and FR Alexium technologies. As part of the new organizational structure, Mr. Estes has been promoted to Vice President, Research and Development. Mr. Estes has a Bachelor of Chemistry from the University of Massachusetts at Amherst and has over 25 years of experience in materials science across a range of industries, including coatings and textiles.

-CONTINUED-

-CONTINUED-

Dr. Brookins stated, "Over the past 18 months, Alexium has made great strides in the three cornerstone initiatives based on our PCM and FR platform technologies. Building on this momentum and leveraging our strengths in innovation and commercialization to progress such initiatives will be my focus, because the Company's profitability and success will be driven by these. I look forward to leading the Alexium team to accomplish this."

Sue Thomas said, "It has been a pleasure to work with Dr. Brookins in the last two months since I have become Chairman. In this period, Bob has demonstrated that he has the leadership qualities to deliver value to shareholders, including delivering on the three cornerstone initiatives. Importantly, two of these initiatives are currently ahead of target, and I am confident that with Bob's leadership and his team's commitment, Alexium will be able to demonstrate success in one or more of these areas in the near future."

Summary of key terms of appointment:

Appointment	The appointment is to the position of Chief Executive Officer and Managing Director.
Term	Effective 1 July 2018, no fixed term. Notice period of three months by either party.
Total Fixed Remuneration	Dr. Brookins will be paid a fixed cash remuneration package of US\$296,000 per annum, subject to annual review.
Short Term Incentive	It is anticipated that a short-term incentive package will be negotiated, and the market will be advised when this has been finalized.
Long Term Incentive	It is anticipated that a long-term incentive package will be negotiated, and the market will be advised when this has been finalized.

Attached is Dr. Brookins' Initial Directors Interest Notice (Appendix 3X).

About Alexium International Group Limited

Alexium International Group Limited (ASX: AJX, Nasdaq Designation: AXXIY) holds proprietary patent applications for novel technologies developed to provide flame retardancy for a wide range of materials. These environmentally friendly flame retardants have applications for several industries and can be customized. Further, Alexium has developed products for a range of other applications including phase-change materials, water repellents, antimicrobials, and combinations thereof. Alexium also holds patents for a process developed initially by the U.S. Department of Defense, which allows for the surface modification and attachment of nanoparticles or multiple chemical functional groups to surfaces or substrates to provide functions such as fire retardancy, water proofing, oil proofing, and antimicrobial treatments. Applications under development include but are not limited to textiles, packaging, electronics, and building materials. Alexium's chemical treatments are currently marketed as Alexicool® and Alexiflam®. For additional information about Alexium, please visit www.alexiuminternational.com.

U.S. Contact	U.S. Corporate Office	Listing Information
Mark Wise, VP Investor Relations mwise@alexiuminternational.com 1.864.603.1211	350 W. Phillips Rd. Greer, SC 29650 USA US: 1.864.254.9923	ABN: 91 064 820 408 ASX: AJX Nasdaq Designation: AXXIY

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Alexium International Group
ABN	91 064 820 408

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robert Brookins
Date of appointment	12 July 2018

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 2,581,000 Ordinary Fully Paid Shares

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
BNP Paribas Nominees Pty Ltd – Beneficial holder of securities as follows:	
• Director	291,240 Ordinary Fully Paid Shares
• Director's children in trust	290,000 Ordinary Fully Paid Shares

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.